Asheville, NC

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Diabetic eye disease3 trials
• Macular degeneration1 trial

Phase

• Phase 2/32 trials
• Phase 1/21 trial

Status

• Active, not recruiting2 trials
• Completed1 trial

Lead sponsor

• EyeBiotech Ltd.3 trials

Running trials

• Active, not recruiting

  A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06957080· Phase 2/3· EyeBiotech Ltd.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06571045· Phase 2/3· EyeBiotech Ltd.· Source

Closed trials

• Completed

  A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

  NCT06664502· Phase 1/2· EyeBiotech Ltd.· Source